Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers |
| |
| Authors: | Kelly C. Gast Paul V. Viscuse Somaira Nowsheen Tufia C. Haddad Robert W. Mutter Andrea E. Wahner Hendrickson Fergus J. Couch Kathryn J. Ruddy |
| |
| Affiliation: | 1.Department of Internal Medicine,Mayo Clinic School of Graduate Medical Education,Rochester,USA;2.Mayo Clinic Graduate School of Biomedical Sciences,Medical Scientist Training Program, Mayo Clinic School of Medicine,Rochester,USA;3.Department of Oncology, Division of Medical Oncology,Mayo Clinic,Rochester,USA;4.Department of Radiation Oncology,Mayo Clinic,Rochester,USA;5.Department of Laboratory Medicine and Pathology,Mayo Clinic,Rochester,USA |
| |
| Abstract: | Purpose of reviewBRCA1 and BRCA2 mutation carriers can be at increased cardiovascular risk. The goal of this review is to provide information about factors associated with increased cardiovascular risk, methods to prevent cardiovascular toxicities, and recommended screening guidelines.Recent findingsBRCA1/2 mutation carriers who are diagnosed with cancer are often exposed to chemotherapy, chest radiotherapy, and/or HER2 directed therapies, all of which can be cardiotoxic. In addition, BRCA1/2 carriers often undergo prophylactic salpingoopherectomies, which may also increase cardiovascular risks.SummaryUnderstanding the potential for increased cardiovascular risk in individuals with a BRCA1 or BRCA2 mutation, as well as gold standard practices for prevention, detection, and treatment of cardiac concerns in this population, is important. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
